

FOR IMMEDIATE DISTRIBUTION

**GLIKNIK ADDS INCYTE PRESIDENT & CEO PAUL A. FRIEDMAN
TO ITS BOARD OF DIRECTORS**

BALTIMORE, MARYLAND, February 25, 2013 – [Gliknik Inc.](#), a privately held biopharmaceuticals company, today announced the appointment of Incyte Corporation President and Chief Executive Officer [Paul A. Friedman, M.D.](#), to its Board of Directors. Dr. Friedman, a seasoned pharmaceutical industry executive with strong experience in management of R&D and corporate functions, joins Gliknik’s board as the company is continuing to advance its pipeline of drug candidates targeting various cancers and immune disorders.

“It’s an honor for us to welcome Paul to the Gliknik Board of Directors,” said Gliknik CEO [David S. Block](#). “His deep experience in pharmaceutical research, development, commercialization, and business development and his unwavering commitment to excellence bring an important perspective to Gliknik as we seek to advance and to partner our pipeline of novel therapies.”

Dr. Friedman joined Incyte in 2001 as Chief Executive Officer and a Director. A biopharmaceutical company focused on discovering, developing and commercializing proprietary small molecule drugs for oncology and inflammation, Incyte developed and commercialized [Jakafi[®]](#) (ruxolitinib) under Dr. Friedman and has a robust product pipeline. Previously, Dr. Friedman served as President of R&D for the DuPont Merck Pharmaceutical Company, President of DuPont Pharmaceuticals Research Laboratories, and Senior Vice President at Merck Research Laboratories. Prior to his work at Merck and DuPont, Dr. Friedman was an associate professor of medicine and pharmacology at Harvard Medical School. Dr. Friedman is a diplomate of the American Board of Internal Medicine and a member of the American Society of Clinical Investigation. He received his A.B. in biology from Princeton University and his M.D. from Harvard Medical School. Dr. Friedman is also a director of Auxilium Pharmaceuticals, Inc.

“I welcome the opportunity to join the Gliknik Board of Directors and look forward to contributing to its goal of advancing and partnering the company’s clinical [immunomodulator](#) and preclinical [stradomer™](#) programs,” said Dr. Friedman.

About Gliknik Inc.

Founded in 2007, Gliknik is a biopharmaceuticals company creating new therapies for patients with cancer and immune disorders. Gliknik expertise is in modulation of the immune system to fight disease. In addition to the [stradomer™](#) program for autoimmune diseases, Gliknik also has commercial rights to two cancer immunomodulator drugs that are in multiple-dose clinical trials in patients with advanced head and neck cancer and in patients with advanced multiple myeloma. Learn more at www.gliknik.com.

###

Media contact:

[Jamie Lacey-Moreira](#), PressComm PR, 410-299-3310